Tumour matrilysin expression predicts metastatic potential of stage I (pT1) colon and rectal cancers

Gut

Volumn 54, Issue 12, 2005, Pages 1751-1758

  Kurokawa, S ^a,b   Arimura, Y ^a   Yamamoto, H ^a   Adachi, Y ^a   Endo, T ^a   Sato, T ^b   Suga, T ^b   Hosokawa, M ^c   Shinomura, Y ^a   Imai, K ^a  

^a SAPPORO MEDICAL UNIVERSITY   (Japan)

^b Sapporo Kosei General Hospital   (Japan)

^c KEIYUKAI SAPPORO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENTARY DNA; MATRILYSIN; TUMOR PROTEIN;

ADULT; ARTICLE; ARTIFICIAL NEURAL NETWORK; BAYES THEOREM; CANCER RISK; CANCER STAGING; CANCER THERAPY; COLON CANCER; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; HUMAN; HUMAN TISSUE; LOGISTIC REGRESSION ANALYSIS; LYMPH NODE METASTASIS; MALE; MATHEMATICAL MODEL; METASTASIS POTENTIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RECEIVER OPERATING CHARACTERISTIC; RECTUM CANCER; RISK FACTOR; STATISTICAL MODEL; UPREGULATION;

ADENOCARCINOMA; AGED; COLORECTAL NEOPLASMS; DNA, COMPLEMENTARY; DNA, NEOPLASM; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MATRIX METALLOPROTEINASE 7; MIDDLE AGED; MODELS, STATISTICAL; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL; UP-REGULATION;

EID: 28144433493     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2005.071035     Document Type: Article

References (35)

1. Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-42.
2. Moulder SL, Yakes FM, Muthuswamy SK, et al. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo. Cancer Res 2001;61:8887-95.
3. Gordon MS, Margolin K, Talpaz M, et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-50.
4. Zhou W, Goodman SN, Galizia G, et al. Counting alleles to predict recurrence of early-stage colon and rectal cancer. Lancet 2002;359:219-25.
5. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-91.
6. Liefers GJ, Cleton-Jansen AM, van de Velde CJ, et al. Micrometastases and survival in stage II colorectal cancer. N Engl J Med 1998;339:223-8.
7. Woessner JF Jr. Matrix metalloproteinase family. In Parks WC, Mecham RP, eds. Matrix metalloproteinases. California: Academic Press, 1998:219-38.
8. Yoshimoto M, Itoh F, Yamamoto H, et al. Expression of MMP-7 (PUMP-1) mRNA in human colorectal cancers. Int J Cancer. 1993: 54, 614-18.
9. Wilson CL, Heppner KJ, Labosky PA, et al. Intestinal tumorigenesis is suppressed in mice lacking the metalloproteinase matrilysin. Proc Natl Acad Sci U S A 1997;94:1402-7.
10. Yamamoto H, Itoh F, Adachi Y, et al. Relation of enhanced secretion of active matrix metalloproteinases with tumor spread in human hepatocellular carcinoma. Gastroenterology 1997;112:1290-6.
11. Adachi Y, Yamamoto H, Itoh F, et al. Contribution of matrilysin (MMP-7) to the metastatic pathway of human colon and rectal cancers. Gut 1999;45:252-8.
12. Yamamoto H, Adachi Y, Itoh F, et al. Association of matrilysin expression with recurrence and poor prognosis in human esophageal squamous cell carcinoma. Cancer Res 1999;59:3313-16.
13. Ougolkov AV, Yamashita K, Mai M, et al. Oncogenic β-catenin and MMP-7 (Matrilysin) cosegregate in late-stage clinical colon cancer. Gastroenterology 2002;122:60-71.
14. Crawford HC, Fingleton B, Rudolph-Owen LA, et al. The metalloproteinase matrilysin is a target of β-catenin transactivation in intestinal tumors. Oncogene 1999;18:2883-91.
15. Wong SC, Lo ESF, Lee KC, et al. Prognostic and diagnostic significant of β-catenin nuclear immunostaining in colorectal cancer. Clin Cancer Res 2004;344:1401-8.
16. Cross S, Harrison R, Kennedy R. Introduction to neural networks. Lancet 1995;346:1075-9.
17. Tu JV. Advantages and disadvantages of using artificial neural networks versus logistic regression for predicting medical outcomes. J Clin Epidemiol 1996;11:1225-31.
18. Jöreskog KG, Sörbom D. Advances in factor analysis and structural equation models. Cambridge, Massachusetts: Abt Books, 1979.
19. Nelson H, Petrelli N, Carlin A, et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001;93:583-96.
20. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 2001;98:5116-21.
21. Hase K, Shatney C, Johnson D, et al. Prognostic value of tumor "budding" in patients with colon and rectal cancer. Dis Colon Rectum 1993;36:627-35.
22. Bishop CM. Neural networks for pattern recognition. Oxford: Oxford University Press, 1995.
23. Radford MN. Bayesian learning for neural networks. New York: Springer-Verlag, 1996.
24. MacKay DJ. Bayesian interpolation. Neural Computation 1992;4:415-47.
25. Metz CE, Herman BA, Roe CA. Statistical comparison of two ROC curve estimates obtained from partially-paired datasets. Med Decis Making 1998;18:110-21.
26. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trial and tribulations. Science 2002;295:2387-92.
27. Nascimbeni R, Burgart LJ, Nivatvongs S, et al. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum 2002;45:200-6.
28. Masaki T, Muto T. Predictive value of histology at the invasive margin in the prognosis of early invasive colon and rectal cancer. J Gastroenterol 2000;35:195-200.
29. Schlesselman JJ. Case-control studies: Design, conduct, analysis. New York: Oxford University Press, 1982.
30. Hill AB. The environment and disease: association or causation? Proc R Soc Med 1965;58:295-300.
31. Brabletz T, Jung A, Reu S, et al. Variable β-catenin expression in colon and rectal cancers indicates tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 2001;98:10356-61.
32. Crawford HC, Fingleton B, Gustavson MD, et al. The PEA subfamily of Ets transcription factors synergies with β-catenin-LEF-1 to activate matrilysin transcription in intestinal tumors. Mol Cell Biol 2001;21:1370-83.
33. Horiuchi S, Yamamoto H, Min Y, et al. Association of ets-related transcriptional factor E1AF expression with tumor progression and overexpression of MMP-1 and matrilysin in human colorectal cancer. J Pathol 2003;200:568-76.
34. Lee SY, Poon WY, Bentler PM. A two-stage estimation of structural equation models with continuous and polytomous variables. Br J Math Stat Psychol 1995;48:339-58.
35. Bentler PM, Wu EJC. EQS for windows user's guide. California: Multivariate Software Inc, 1995.